Login/Register
  • 中文
  • English

News

Licensing Revenue Boosts HanchorBio’s September Revenue to NT$312 Million

HanchorBio (stock code: Hanchor-KY) reported record-breaking consolidated revenue of NT$312 million in September, driven by the recognition of licensing income from its novel anti-cancer fusion protein drug, HCB101. In functional currency terms, consolidated revenue for September amounted to US$10 million.

Read more
Oct 14, 2025
Heron Neutron Medical to Invest US$30 Million in BenQ Medical Group to Deepen Collaboration in the China Market
Oct 14, 2025
Startup Breakthrough: Surface Hydrogenation Technology Addresses Pain Points in Metal Implant Market
Oct 13, 2025
Leading Argentine Hospital Group Controls 90% of Medical Device Procurement, Sees Strong International Competitiveness of Taiwanese Products
Oct 13, 2025
47 Drugs Withdrawn from Taiwan Market; TFDA Chief Chih-Kang Chiang Assures Clinical Supply Unaffected, Proposes Law Amendment to Mandate Shortage Reporting
Oct 13, 2025
Onyx Healthcare’s September Revenue Surges; Three-Growth Engines Drive Momentum as Q4 Targets Annual Peak
Oct 13, 2025
Global Pharmaceutical Market Reshuffle Brings Dual Benefits for Taiwanese Firms
Oct 13, 2025
Rising CDMO Demand Spurs Expansion at Tanvex BioPharma and EirGenix
Oct 09, 2025
Medeon Biodesign’s Urology Device Achieves New Milestone as Urocross Retrieval Sheath Receives U.S. FDA Clearance
Oct 09, 2025
Tanvex BioPharma Reports Record September Revenue of NT$84.86 Million, a 39-Fold Year-on-Year Increase; Q3 Revenue Surpasses NT$100 Million for the First Time

Most Watched

Recommended

Murata Stretchable Printed Circuit
Taiwan Murata Electronics Co., Ltd
Picoleaf sensor
Taiwan Murata Electronics Co., Ltd
Bile acids analysis
HONG SHENG PRECISION BIOTECH CO., LTD.

Industry Watch

Read more